SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company believes that current market conditions are not conducive to an offering.</li><li>It had filed for a public offering of 2 million of its common stock with the U.S. SEC.</li><li>Jet.AI intended to use the net proceeds from the sales of the securities primarily for further development of announced and pending data center projects.</li></ul>Shares of Jet.AI (<a href="https://stocktwits.com/symbol/JTAI">JTAI</a>) surged more than 5% on Tuesday after the company announced it had withdrawn the underwritten public offering of its common stock, almost a month after the offering was announced.The firm stated that current market conditions were not conducive to an offering on terms that would be in the best interests of its stockholders.It had earlier filed a public offering with the Securities and Exchange Commission, stating it was offering two million shares of its common stock at $2 per share. The firm intended to use the net proceeds from the sales of the securities primarily for its general working capital needs, the further development of announced and pending data center projects, and its ongoing operations in the data center space.Jet.AI, founded in 2018, is based in Las Vegas and operates in two segments, Software and Aviation, and is transitioning to a pure-play AI data center company.<h2 class="st-heading-2">AI Pivot</h2>Jet.AI last week announced a planned joint venture with Choo Choo Express (CCE) to develop a 50-megawatt data center campus in Moapa, Clark County, Nevada. It expects to commit about $10 million of capital over an anticipated two-year period.As part of its transition plans, Jet.AI sold its aviation business to flyExclusive (FLYX) earlier this year. As part of the deal, Jet.AI shareholders retained their Jet.AI stock and received new Class A common shares in flyExclusive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment in JTAI trended in ‘bearish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:632/71;" src="https://news.stocktwits-cdn.com/jtai_PNG_0da8781799.webp" alt="Retail sentiment in JTAI trended in ‘bearish’ territory amid ‘extremely high’ message volumes." width="632" height="71"></figure>Shares in JTAI have fallen more than 84% so far in 2025. &nbsp;

In Barcelona, Spain, on March 5, 2025, a close-up of AI cloud data center racks with servers, cables, and blinking lights. (Photo by Joan Cros/NurPhoto via Getty Images)

What’s Behind Jet.AI Stock’s Rally Today?

Jet.AI on Tuesday withdrew the public offering of its common shares, nearly a month after it filed with the U.S. SEC.

Equity

<ul class="summary-bullets"><li>Hyperscale Data’s total Bitcoin treasury reached $76.1 million as of Dec.28</li><li>The company aims to reach $100 million in Bitcoin on its balance sheet.</li><li>Additionally, its wholly owned subsidiary, Sentinum, currently holds approximately 519.6787 Bitcoin.</li></ul>Hyperscale Data Inc. (<a href="https://stocktwits.com/symbol/GPUS">GPUS</a>) shares gained over 2% premarket after reporting a $76.1 million Bitcoin treasury as of Dec. 28.This figure—both direct holdings and cash for Bitcoin purchases—now accounts for roughly 117.8% of the company's market capitalization, based on its stock price at the close of trading on December 29, 2025.<h2 class="st-heading-2">$100M Bitcoin On Balance Sheet Target</h2>The company said that after reaching its target of 100% of its market capitalization in Bitcoin, its next goal is to add $100 million in Bitcoin to its balance sheet. It said that it will fully deploy the cash allocated to its digital asset treasury (DAT) strategy into Bitcoin purchases over time.In September, the company unveiled its $100 million BTC treasury plan, funded by selling Montana data center assets and through an at-the-market equity sale.<h2 class="st-heading-2">Subsidiary Sentinum’s Bitcoin Holdings</h2>Sentinum, Hyperscale’s subsidiary, holds 519.6787 Bitcoin, acquired through mining and open-market purchases, worth about $45.6 million, given Bitcoin's closing price of $87,836 as of Dec. 28, 2025.The company is setting aside $30.5 million for Sentinum to accelerate open-market Bitcoin buys.<h2 class="st-heading-2">Growing DAT Adoption</h2>Firms globally are adopting DATs to put digital currencies on their balance sheets, as interest in the sector continues to surge.DLA Piper reports over 200 companies adopted DATs by September 2025: 190 focused on BTC, 10–20 on other assets.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around Hyperscale stock trended in ‘extremely bearish’ territory amid ‘low’ message volume.&nbsp;<figure class="image"><img style="aspect-ratio:631/76;" src="https://news.stocktwits-cdn.com/GPUS_PNG_231ee3953f.webp" alt="retail sentiment around Hyperscale stock trended in ‘extremely bearish’ territory amid ‘low’ message volume. " width="631" height="76"></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp; &nbsp;

In this photo illustration, the Hyperscale Data logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

What’s Behind Hyperscale Data’s Surge Today?

Hyperscale shares jump premarket as its bitcoin treasury exceeds its market cap at 117.8%

<ul class="summary-bullets"><li>Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio.</li><li>The firm will use the proceeds from the sale of Pocono Pharma to continue developing AVERSA Fentanyl.</li><li>It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.</li></ul>Shares of Nutriband Inc. (<a href="https://stocktwits.com/symbol/NTRB">NTRB</a>) surged more than 18% on Monday after the company announced an agreement to sell 90% stake in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million.Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio following the acquisition, it stated.Nutriband will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl. The company develops transdermal drug delivery systems that are focused on preventing abuse and misuse of medications like opioids using its proprietary AVERSA Technology.<h2 class="st-heading-2">Bet On Abuse-Deterrent Aversa Fentanyl</h2>The U.S. government has been cracking down on illicit fentanyl. U.S. President Donald Trump earlier this month signed an executive order designating it as a weapon of mass destruction and recognizing the substance as a direct threat to U.S. national security.Nutriband’s AVERSA Fentanyl uses its abuse-deterrent technology, which is designed to improve the safety profile of transdermal drugs that are susceptible to abuse, such as fentanyl, while making sure these drugs remain accessible to patients who need them.Nutriband has been partnering with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.Nutriband had signed a non-binding Letter of Intent (LOI) with Qvanta Group of Companies to explore potential collaboration areas, including secure AI and analytics platforms for regulated pharmaceutical data, and cybersecurity that support abuse-deterrent technologies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:639/68;" src="https://news.stocktwits-cdn.com/ntrb_PNG_d487765902.webp" alt="Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes. " width="639" height="68"></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

What’s Driving Nutriband Shares Higher Today?

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million. 

<ul class="summary-bullets"><li>The company has been selected as one of the contract awardees under the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) contract with a ceiling of $151 billion.&nbsp;</li><li>Sidus Space announced the closing of a public offering of about 19 million shares, raising approximately $25 million.&nbsp;</li><li>Retail investors remain bullish on the stock, with some eyeing a share price above $10.</li></ul>Shares of Sidus Space Inc. (SIDU) have gained over 218% in the past month, but despite the massive rally, retail investors continue to remain bullish on the stock.Some investors expect the shares to cross the $10 mark. At the time of writing, SIDU shares traded near $2.9. The optimism around the company comes largely from two major headlines this month – the company won a contract from the Missile Defense Agency (MDA), and almost immediately, it announced the pricing of a public offering of 19 million shares.<h2 class="st-heading-2">The Defense Contract</h2>On Dec. 22, 2025, Sidus Space announced that it was selected as one of the contract awardees under the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) contract. The SHIELD contract is part of the broader Golden Dome missile defense strategy in the U.S., which focuses on building protection against air, missile, space, cyber, and hybrid threats.The indefinite-delivery/indefinite-quantity (IDIQ) contract was awarded with a $151 billion ceiling. While an IDIQ is not a guarantee, it does make Sidus Space eligible to compete for future task orders issued under the contract.The space company currently has a market capitalization of about $119 million.<h2 class="st-heading-2">Public Stock Offering&nbsp;</h2>Shortly after the defense contract announcement, on Dec. 24, 2025, Sidus Space announced the closing of a public offering of about 19 million shares, raising approximately $25 million. The company said that it intends to use the proceeds for sales and marketing, operational costs, product development, manufacturing expansion, working capital, and general corporate needs.The sale announcement came amid growing interest in space technology companies following President Donald Trump's announcement of a new U.S. space policy.While most retail optimism surrounded the defense contract and public stock offering, Sidus Space also completed the initial bus-level commissioning of its LizzieSat-3 satellite this month. The company said it would enable payload operations and delivery of autonomous, AI-enabled sensor data to government and commercial customers.Separately, the company announced that it would act as a subcontractor on a NASA-funded Small Business Innovation Research (SBIR) design study to integrate a space-based radar payload onto its LizzieSat platform, supporting orbital debris tracking and space domain awareness.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around SIDU stock has remained in the ‘extremely bullish’ territory over the past week. A month ago, retail sentiment on the stock was in the ‘bearish’ territory. At the same time, message volume around the stock has been ‘extremely high’ over the past week.<figure class="image"><img style="aspect-ratio:1298/163;" src="https://news.stocktwits-cdn.com/SIDU_sentiment_and_message_Dec_26_png_2d92b812cf.webp" alt="On Stocktwits, retail sentiment around SIDU stock has remained in the ‘extremely bullish’ territory over the past week. " width="1298" height="163"></figure>&nbsp;One user called the company ‘baby Palantir’ because it's a multi-day runner. They added that their bullish sentiment on the company stems from its long-term upside driven by converging space, defense, and AI-driven data benefits.<stembedurl>https://stocktwits.com/stocks_kid/message/640148882</stembedurl>&nbsp;Another bullish user predicted that its shares would rise to over $10.<stembedurl>https://stocktwits.com/fzriderz/message/640147475</stembedurl>&nbsp;However, one bearish user warned that Sidus Space is just among many companies selected for the Golden Dome contract, and that there was ‘nothing special’.<stembedurl>https://stocktwits.com/cw6799/message/640151059</stembedurl>&nbsp;<a href="https://stocktwits.com/symbol/SIDU">Shares of SIDU</a> are down over 53% in the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Sidus Space logo is seen displayed on a smartphone screen. 

Sidus Space Stock Is Up 218% This Month — Why Are Retail Investors Still Bullish? 

Sidus Space shares are rallying after the company gained a major defense contract and announced a public offering of 19 million shares this month. 

<ul class="summary-bullets"><li>Needham maintained a “Buy” rating with a $300 price target for Reddit</li><li>The firm says Reddit is the fastest-growing company in its coverage.</li><li>Needham added Reddit to its ‘Conviction buy’ list, replacing Roku.</li></ul>Reddit’s stock (<a href="https://stocktwits.com/symbol/RDDT">RDDT</a>) was in the spotlight on Tuesday after analysts at Needham named it as its top pick for 2026 and added the stock to its ‘Conviction buy’ list by replacing Roku. Needham maintained its “Buy” rating, with a $300 price target, citing the platform’s 100% human-created content as the key differentiator.According to TheFly, analysts at Needham believe Reddit’s authentic content optimizes trust and value for large language models (LLMs), making it attractive.They added that Reddit already generates over $100 million per year in fees from OpenAI and Google's Gemini, and this could double with Anthropic and Perplexity fees.Needham also noted that Reddit is the fastest-growing company in its coverage, while its Performance Ads offer "full-funnel ad solutions" and a larger share of ad budgets.<h2 class="st-heading-2">OpenAI, Google AI Content Licensing Deal</h2>Reddit has been partnering with OpenAI since 2024 to bring its content to ChatGPT under the deal. In this arrangement, both OpenAI and ChatGPT use Reddit’s application programming interface, which also distributes Reddit's content. As part of the deal, OpenAI also became Reddit's advertising partner.Before its IPO, Reddit had also struck an AI content licensing deal with Google worth about $60 million per year, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/technology/reddit-ai-content-licensing-deal-with-google-sources-say-2024-02-22/">report</a> from Reuters. The deals underscored the company's efforts to generate more revenue amid fierce competition from other major players, such as Meta’s Facebook.<h2 class="st-heading-2">AI Bet Paying Off</h2>Reddit has been seeing its AI-powered advertising tools attract more marketing spending on the platform. During the third quarter (Q3) earnings call, its Chief Operating Officer, Jen Wong, told analysts that Reddit’s total active advertiser count expanded by over 75% year-over-year.It has prompted Reddit to forecast current-quarter revenue at the higher end of analyst estimates, according to Fiscal.ai data. The company expects fourth quarter revenue (Q4) to be between $655 million and $665 million, in line with analyst projections of $665 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around the RDDT trended in “bearish” territory amid “normal” message volume.&nbsp;<figure class="image"><img style="aspect-ratio:643/71;" src="https://news.stocktwits-cdn.com/rddt_PNG_ec1f193863.webp" alt="Retail sentiment around the RDDT trended in “bearish” territory amid “normal” message volume. " width="643" height="71"></figure> For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect the correct name of Reddit's COO.

In this photo illustration, a Reddit logo is seen displayed on a smartphone with an Artificial Intelligence (inscriptions) in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Why Reddit Is Needham’s ‘Top Pick’ For 2026 After A 40% Surge

Analysts cite Reddit’s 100% human-created content and fast-growing ad platform as key drivers of future revenue.

Why Reddit Stock Is Needham’s ‘Top Pick’ For 2026 After A 40% Surge

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

<ul class="summary-bullets"><li>Under the deal, EVTV would acquire 100% of AZIO AI’s outstanding shares.</li><li>Upon completion, EVTV's long-term strategy would pivot to focus on AI infrastructure and applied artificial intelligence systems.&nbsp;</li><li>The rapid growth of companies like CoreWeave underscores the scale of demand for enterprise-grade AI compute infrastructure, AZIO’s CEO said.</li></ul>Envirotech Vehicles, Inc. (<a href="https://stocktwits.com/symbol/EVTV">EVTV</a>) shares climbed nearly 10% in Thursday’s premarket trade after additional details about its AZIO AI acquisition deal valued the infrastructure player at $480 million.AZIO AI issued a letter of intent on Thursday stating that an independent third party valued the company and that EVTV would acquire 100% of its outstanding shares. Upon completion of the deal, EVTV would reposition its long-term strategy to focus on AI infrastructure and applied artificial intelligence systems.Earlier this week, Envirotech Vehicles announced the AZIO deal, indicating its evolution into an AI infrastructure platform, shifting away from its current focus on manufacturing electric vehicles and heavy-capacity drones.<h2 class="st-heading-2">CoreWeave-Style Model</h2>The latest pivot comes amid increasing global demand for artificial intelligence and enterprise-grade GPU systems. The deal would frame AZIO AI as the primary operating entity, leveraging EVTV’s public market presence. EVTV has a market capitalization of about $3.86 million at the time of writing."The rapid growth of publicly traded AI infrastructure companies such as CoreWeave, which has achieved an approximately $32 billion market capitalization, underscores the scale of demand for dedicated, enterprise-grade AI compute infrastructure. We believe there is a substantial opportunity to build a competitive, publicly traded, infrastructure-first AI company by delivering scalable GPU compute, modular data-center deployments, and flexible, capital-efficient solutions for governments, institutions, and enterprises," said Chris Young, Chief Executive Officer of AZIO AI.EVTV is the latest among numerous smaller public companies shifting focus toward AI systems and data-center infrastructure, even as markets worry about inflated AI valuations. Bitcoin mining company Hut 8 Corp. (HUT) announced on Wednesday that it had signed a $7 billion lease for an AI data center with Fluidstack. Cipher Mining (<a href="https://stocktwits.com/symbol/CIFR">CIFR</a>) and TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) announced similar pivots to AI infrastructure in the past few months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around EVTV remained at ‘extremely bullish’ levels for over a week and message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1273/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_5_08_52_PM_png_5928e5ebd2.webp" alt="On Stocktwits, the retail sentiment around EVTV remained at ‘extremely bullish’ levels for over a week and message volume stayed at ‘extremely high’ levels." width="1273" height="150"></figure>Shares of EVTV are down over 93% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A computer with the acronym AI for Artificial Intelligence.

Why Are EVTV Shares Climbing Nearly 10% Today?

An independent third-party valuation estimates AZIO AI’s value at $480 million under Envirotech Vehicles’ proposed acquisition deal.

This $4M Microcap EV Player Is Making A $480M AI Infrastructure Pivot

<ul class="summary-bullets"><li>The take-private deal comes at a 50% premium to ISPO’s closing price as of Dec. 16, 2025.&nbsp;</li><li>Exclusive Investments will pay $4.27 per share in an all-cash transaction expected to close in early 2026.</li><li>Current Chairman and CEO, Payam Zamani, will step down after the deal.</li></ul>Inspirato Incorporated (<a href="https://stocktwits.com/symbol/ISPO">ISPO</a>) shares soared over 46% on Wednesday after the company announced a take-private deal just about four years after its public listing.The luxury vacation company will be acquired by Exclusive Investments LLC for $59 million, indicating approximately a 50% premium to ISPO’s closing price on Dec. 16, 2025. The deal is expected to close in early 2026.The deal comes amid significant financial and operational challenges for Inspirato. Chairman and CEO of the company, Payam Zamani, indicated that the deal would be a positive step for stakeholders after a year’s effort to stabilize and strengthen the business.<h2 class="st-heading-2">Deal Contours</h2>Exclusive Investments, a noted luxury travel and real estate company, will pay $4.27 per share in an all-cash transaction approved by the Board. Notably, Inspirato’s largest shareholder is Zamani, currently controlling about 36% of the company’s common stock. Zamani has approved the deal and agreed to vote his shares in favor of the transaction.After going private, Zamani is expected to step down from his role as Chairman and Chief Executive Officer. James Henderson, CEO of The Exclusive Collective and Exclusive Resorts, will take over as the interim CEO of the company.“Following a year dedicated to stabilizing and strengthening the business, this agreement represents another positive step forward for Inspirato’s customers, employees, partners, and shareholders,” Zamani said.<h2 class="st-heading-2">Financial Challenges</h2>Inspirato has indicated several financial challenges in the recent past. In its latest quarterly results, the company reported a nearly 20% decline in revenues from the same period last year and about 15% drop for the nine months in 2025. Occupancy rates for the quarter also declined to 56% from 73%.In June this year, Inspirato announced a deal to combine with Buyerlink, a marketing technology platform, through a reverse merger. The deal aimed to transform Inspirato from a standalone luxury travel club into a technology-driven marketplace business spanning luxury travel, automotive, and home services. However, the deal was terminated in September.Inspirato went public in Feb. 2022 through a merger with Thayer Ventures.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around ISPO jumped to ‘extremely bullish’ from ‘neutral’ levels a day ago, and message volume jumped to ‘extremely high’ from ‘low’ levels.<figure class="image"><img style="aspect-ratio:1277/169;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_17_at_9_18_50_PM_png_1596fe3232.webp" alt="On Stocktwits, the retail sentiment around ISPO jumped to ‘extremely bullish’ from ‘neutral’ levels a day ago, and message volume jumped to ‘extremely high’ from ‘low’ levels." width="1277" height="169"></figure>Shares of ISPO are up over 27% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/11: In this photo illustration, the Inspirato Incorporated logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ISPO Jumps 46% On Take-Private Deal Just Four Years After Its IPO

Inspirato Incorporated (ISPO) shares soared over 46% on Wednesday after the company announced a take-private deal just about four years after its public listing.

Luxury vacation company Exclusive Investments will take over Inspirato in a deal valued at $59 million. 


<ul class="summary-bullets"><li>Operational and execution risks have come into sharper focus, with data center construction delays, revised timelines, and infrastructure bottlenecks raising concerns.</li><li>Financial pressures continue to weigh on sentiment, as heavy capital expenditure, a reduced forward outlook, and a speculative credit rating underscore the company’s high-risk, high-reward profile.</li><li>Retail traders and several Wall Street firms continue to bet on a rebound driven by long-term demand for AI.</li></ul>Artificial intelligence (AI) datacenter operator CoreWeave, Inc.’s (CRWV) fortunes have quickly reversed. From a high-profile initial public offering (IPO) in March this year and a meteoric two-month rally that kicked off in late April, <a href="https://stocktwits.com/symbol/CRWV">CoreWeave’s stock</a> has lost much of its momentum as skeptics sowed doubt in investors' minds, who were&nbsp;going all in on&nbsp;any AI play.Even so, the stock is still sitting on handsome gains. What has changed is that much of the nearly 370% return it generated at its intraday peak in late June has evaporated, leaving loyal investors wondering whether the heydays will return.<img src="https://news.stocktwits-cdn.com/CRWV_YTD_Stock_Trajectory_png_d7bd286a31.webp" alt="CRWV YTD Stock Trajectory.png">Source: Koyfin<h2 class="st-heading-2">What Precipitated the Down Move</h2>CoreWeave's hot post-IPO rally stalled after the stock hit a peak in late July.&nbsp; As investors paused for a breather, the Michael Intrator-led company spooked investors by announcing a $9 billion all-stock deal to buy Bitcoin miner Core Scientific, which had also branched out into AI data centers. The agreement has since then been shelved. An expanded AI cloud deal with OpenAI, valued at up to $4 billion, helped to reverse the downtrend. The rally attempt fizzled out in mid-August despite second-quarter results that outperformed expectations. Some blamed the stock slide on the bigger loss it reported for the quarter.&nbsp;After a modest recovery from the post-earnings slide, CoreWeave moved sideways, before the third-quarter earnings report, released in early November, triggered another round of selling in the stock. A delay in the data center infrastructure coming online prompted the company to reduce its forward-looking guidance, exerting downward pressure on the stock.Following the Q3 report, Macquarie analyst Paul Golding, who remains on the sidelines of the stock, cut the price target to $115 from $145. The analyst attributed the action to the use of a lower valuation multiple to reflect the persistently high capital expenditure (capex). He, however, sees room for earnings improvement.Capex, however, declined in the third quarter due to delays at a third-party data center developer, pushing the delivery timeline for "powered shell" capacity.<figure class="table" style="width:94.66%;"><table class="ck-table-resized"><colgroup><col style="width:31.52%;"><col style="width:20.9%;"><col style="width:25.56%;"><col style="width:22.02%;"></colgroup><tbody><tr><td>&nbsp;</td><td>Q1'25</td><td>Q2'25</td><td>Q3'25</td></tr><tr><td>Capex</td><td>$1.9B</td><td>$2.9B</td><td>$1.9B</td></tr></tbody></table></figure>&nbsp; &nbsp; &nbsp; &nbsp; Data source: Earnings call transcriptThe losses were exacerbated by the AI pessimism that was beginning to grip the market around that time. The recovery seen since late November proved short-lived, and the stock has been in a five-session losing streak since Dec. 9.<img src="https://news.stocktwits-cdn.com/CRWV_YTD_Returns_png_7091a212f6.webp" alt="CRWV YTD Returns.png">Source: KoyfinCoreWeave now has 41 data centers, with eight of them coming online in the third quarter. The data center capacity corresponds to 90 megawatts of active power and 2.9 gigawatts of contracted power, according to an S&amp;P <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3492923">report.</a> The firm sees looming risks if the company faces construction or performance issues arising from the data center infrastructure, potentially coming online later than planned.S&amp;P rated CoreWeave's $2.25 billion 1.75% senior unsecured convertible notes, due 2031, a 'B' — suggesting speculative or junk grade. The Recovery Rating is '5,' indicating a low probability (30%) of recovery.&nbsp;<h2 class="st-heading-2">Delays Dent Progress?</h2>In an exclusive report published on Tuesday, the Wall Street Journal<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/tech/ai/coreweave-stock-market-ai-bubble-a3c8c321">&nbsp;said</a> unexpectedly turbulent rainstorms in North Texas caused a roughly 60-day delay at a construction site in Denton.The data center cluster, with 260 megawatt computing capacity, which CoreWeave planned to lease to OpenAI, is now pushed back several months, the report said. It is also noted that revised design plans have delayed some of the data center projects that one of the company's partners was building for it in Texas and elsewhere.<h2 class="st-heading-2">Short Attack</h2>Following the Q3 report, short seller Jim Chanos piled on misery to the stock by <a href="https://stocktwits.com/news-articles/markets/equity/jim-chanos-joins-michael-burry-in-sounding-ai-alarm/cLPIZeRRE59">questioning</a> the company's accounting practices, including its use of a longer depreciation period. Even with a longer depreciable life, CoreWeave's third-quarter numbers suggest the company is barely profitable, he said in a post on X.&nbsp;<h2 class="st-heading-2">What Retail Traders Feel About CRWV Stock</h2>After the stock slump, CoreWeave retail investors have shed their cautious stance and have jumped onto the bullish bandwagon. On Stocktwits, retail sentiment toward the stock was 'bullish' as of early Wednesday.<figure class="image"><img style="aspect-ratio:735/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_17_at_12_24_16_AM_png_b341e134f4.webp" alt="Screenshot 2025-12-17 at 12.24.16 AM.png" width="735" height="436"></figure>&nbsp;A retail trader hinged his <a href="https://stocktwits.com/Cybermoon/message/639390500">expectations</a> on a potential "V-shaped" recovery in the stock following its five sessions of losses in a row. Another user hoped for a short-covering rally. According to Koyfin, short interest in the stock is elevated at 6.60%, down from the September highs of 11%.<img src="https://news.stocktwits-cdn.com/CRWV_short_interest_png_72b08cfb62.webp" alt="CRWV short interest.png">Source: KoyfinMore than half of the analysts covering the stock have 'Buy' or 'Strong Buy' ratings, and 11 remain on the sidelines, and only 2 have sell-equivalent ratings, according to Koyfin's database. The average analyst price target for the stock is $130.96, implying nearly 90% upside from current levels.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/how-ford-and-gm-stocks-quietly-beat-tesla-and-rivian-this-year/cLeJfyRREYw">&nbsp;Detroit Strikes Back: How Ford And GM Stocks Quietly Beat Tesla And Rivian This Year</a>

CoreWeave logo is displayed on a mobile phone, with the company's branding visible in the background, in this photo illustration in Brussels, Belgium, on November 10, 2025. 

CoreWeave’s Post-IPO Surge Fades: Investors’ AI Fears Leave Stock In A Tight Spot

Heavy capital spending, data center delays, accounting scrutiny, and waning AI enthusiasm have weighed on CoreWeave’s shares, even as retail traders stay bullish and analysts still see meaningful upside.

<ul class="summary-bullets"><li>DFLI shares will start trading on a split-adjusted basis on December 18.&nbsp;</li><li>The company will trade on Nasdaq under the same ticker.&nbsp;</li><li>Following the reverse split, DFLI’s outstanding shares will reduce to about 12.1 million from 120.8 million at present.</li></ul>Shares of Dragonfly Energy Holdings Corp. (DFLI) tumbled over 44% in Tuesday’s premarket trade after the company announced a 1-for-10 reverse stock split.DFLI stock will begin trading on a split-adjusted basis on December 18 and will retain its current ticker on Nasdaq.After the reverse stock split, DFLI’s number of shares of common stock outstanding will reduce to about 12.1 million from the current 120.8 million, the company said.<h2 class="st-heading-2">Split Details</h2>The battery technology company’s shareholders approved the reverse split on October 15 at an authorized ratio in the range of 1-for-2 and 1-for-50 and its Board approved the 1-for-10 reverse split on December 2.“Recent capital raises and debt restructuring have materially strengthened our balance sheet and improved liquidity. With a more durable financial foundation, Dragonfly is focused on scaling revenue, deepening strategic partnerships, and investing in differentiated battery technologies that support long-term value creation,” said Dr. Denis Phares, Chief Executive Officer of Dragonfly Energy, clarifying the company’s future goals.Dragonfly Energy is primarily a lithium battery maker, most known for its Battle Born Batteries brand. Earlier this month, the company partnered with National Railway Supply to power the firm’s first lithium battery line. The announcement came after the American Railway Engineering and Maintenance-of-Way Association released its first lithium battery standard.In November, <a href="https://stocktwits.com/symbol/DFLI">DFLI</a> reported third quarter (Q3) 2025 results, posting $16 million in net sales that marked a 25.5% increase from the previous year. The company’s gross margins grew 710 basis points to 29.7% although it reported a net loss of $11.1 million, up from a loss of $6.8 million in the previous year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around DFLI remained ‘bullish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_16_at_7_15_54_PM_png_2aff3d75b8.webp" alt="Screenshot 2025-12-16 at 7.15.54 PM.png">One user shared their ‘bullish’ stance on DFLI, noting that the stock seems oversold compared to its market capitalization.<stembedurl>https://stocktwits.com/JBankes/message/639284631</stembedurl>Shares of DFLI have plunged more than 78% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Dragonfly Energy logo is seen displayed on a smartphone screen. 

Why Did Dragonfly Energy Shares Plunge 44% Today?

Shares of Dragonfly Energy Holdings Corp. (DFLI) tumbled over 44% in Tuesday’s premarket trade after the company announced a 1-for-10 reverse stock split.

Dragonfly Energy announced a 1-for-10 reverse stock split on Tuesday. 

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF